DXCM Stock Overview
A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.37 |
| 52 Week High | US$130.70 |
| 52 Week Low | US$58.07 |
| Beta | 1.17 |
| 11 Month Change | 6.94% |
| 3 Month Change | 8.15% |
| 1 Year Change | -29.91% |
| 33 Year Change | -47.11% |
| 5 Year Change | n/a |
| Change since IPO | -23.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| DXCM | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 1.9% | -0.2% | 1.1% |
| 1Y | -29.9% | 10.6% | 1.2% |
Return vs Industry: DXCM underperformed the Austrian Medical Equipment industry which returned 10.6% over the past year.
Return vs Market: DXCM underperformed the Austrian Market which returned 1.2% over the past year.
Price Volatility
| DXCM volatility | |
|---|---|
| DXCM Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.5% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: DXCM's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: DXCM's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 9,550 | Kevin Sayer | www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
DexCom, Inc. Fundamentals Summary
| DXCM fundamental statistics | |
|---|---|
| Market cap | €28.04b |
| Earnings (TTM) | €649.48m |
| Revenue (TTM) | €3.77b |
42.7x
P/E Ratio7.4x
P/S RatioIs DXCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXCM income statement (TTM) | |
|---|---|
| Revenue | US$3.95b |
| Cost of Revenue | US$1.52b |
| Gross Profit | US$2.44b |
| Other Expenses | US$1.76b |
| Earnings | US$680.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.74 |
| Gross Margin | 61.68% |
| Net Profit Margin | 17.22% |
| Debt/Equity Ratio | 123.3% |
How did DXCM perform over the long term?
See historical performance and comparison